Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ganglioside GM1 in Acute Ischemic Stroke
NCT04952064Phase 4Completed
- Sponsor
- General Hospital of the Northern Theater Command
- Start
- Jul 2021
- Primary completion
- Jul 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of monosialotetrahexosylganglioside in ischemic stroke, sponsored by General Hospital of the Northern Theater Command. Started Jul 2021; status: completed.
02
Drugs
monosialotetrahexosylganglioside
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT04952064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04952064.